Consolidated Statements of Changes in Stockholders' Deficit - USD ($) |
Common Stock
2023 Equity Line of Credit Agreement
|
Common Stock
2024 Direct Offering
|
Common Stock
2024 At the Market Offering Agreement
|
Common Stock
2024 Private Placement Offering
|
Common Stock
2025 Equity Line Of Credit Agreement
Lincoln Park Capital Fund
|
Common Stock
2025 Equity Purchase Agreement
Triton Funds L.P.
|
Common Stock |
Additional Paid-In Capital
2023 Equity Line of Credit Agreement
|
Additional Paid-In Capital
2024 Direct Offering
|
Additional Paid-In Capital
2024 At the Market Offering Agreement
|
Additional Paid-In Capital
2024 Private Placement Offering
|
Additional Paid-In Capital
2025 Equity Line Of Credit Agreement
Lincoln Park Capital Fund
|
Additional Paid-In Capital
2025 Equity Purchase Agreement
Triton Funds L.P.
|
Additional Paid-In Capital |
Accumulated Deficit |
2023 Equity Line of Credit Agreement |
2024 Direct Offering |
2024 At the Market Offering Agreement |
2024 Private Placement Offering |
2025 Equity Line Of Credit Agreement
Lincoln Park Capital Fund
|
2025 Equity Purchase Agreement
Triton Funds L.P.
|
Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beginning Balance at Dec. 31, 2023 | $ 11,000 | $ 515,927,000 | $ (518,303,000) | $ (2,365,000) | ||||||||||||||||||
| Beginning Balance (in shares) at Dec. 31, 2023 | 10,645,049 | |||||||||||||||||||||
| Net Income (Loss) | (13,094,000) | (13,094,000) | ||||||||||||||||||||
| Issuance of common stock | $ 1,000 | $ 1,000 | $ 1,000 | $ 1,000 | $ 1,900,000 | $ 4,829,000 | $ 714,000 | $ 1,837,000 | $ 1,901,000 | $ 4,830,000 | $ 715,000 | $ 1,838,000 | ||||||||||
| Issuance of common stock (in shares) | 949,574 | 1,371,000 | 1,073,050 | 1,248,527 | ||||||||||||||||||
| Common stock issued under Warrant Inducement Agreement, net of issuance costs of $277 | $ 2,000 | 1,860,000 | 1,862,000 | |||||||||||||||||||
| Common stock issued under Warrant Inducement Agreement, net of issuance costs of $277 (in shares) | 1,711,111 | |||||||||||||||||||||
| Reclassification of Warrant Liability upon Exercise | 245,000 | 245,000 | ||||||||||||||||||||
| Common stock issued under 2024 Securities Purchase Agreements | 11,000 | 11,000 | ||||||||||||||||||||
| Common stock issued under 2024 Securities Purchase Agreements (in shares) | 9,733 | |||||||||||||||||||||
| Common stock issued for exercised warrants (in shares) | 200,000 | |||||||||||||||||||||
| Common stock issued for vested restricted stock awards | 161,000 | 161,000 | ||||||||||||||||||||
| Common stock issued for vested restricted stock awards (in shares) | 199,076 | |||||||||||||||||||||
| Stock-based compensation expense | 1,333,000 | 1,333,000 | ||||||||||||||||||||
| Ending Balance at Dec. 31, 2024 | $ 17,000 | 528,817,000 | (531,397,000) | (2,563,000) | ||||||||||||||||||
| Ending Balance (in shares) at Dec. 31, 2024 | 17,407,120 | |||||||||||||||||||||
| Net Income (Loss) | (12,780,000) | (12,780,000) | ||||||||||||||||||||
| Issuance of common stock | $ 12,000 | $ 1,000 | $ 3,325,000 | $ 412,000 | $ 24,000 | $ 3,337,000 | $ 412,000 | $ 25,000 | ||||||||||||||
| Issuance of common stock (in shares) | 12,277,441 | 824,493 | 354,988 | |||||||||||||||||||
| Common stock issued for convertible notes settlement | $ 6,000 | 910,000 | 916,000 | |||||||||||||||||||
| Common stock issued for convertible notes settlement (in shares) | 5,465,850 | |||||||||||||||||||||
| Common stock issued under Private Placement Offering, net of issuance costs | $ 7,000 | 2,802,000 | 2,809,000 | |||||||||||||||||||
| Common stock issued under Private Placement Offering, net of issuance costs (in shares) | 6,550,000 | |||||||||||||||||||||
| Common stock issued for exercised warrants | 381,000 | 381,000 | ||||||||||||||||||||
| Common stock issued for exercised warrants (in shares) | 450,000 | |||||||||||||||||||||
| Common stock issued for vested restricted stock awards | 102,000 | 102,000 | ||||||||||||||||||||
| Common stock issued for vested restricted stock awards (in shares) | 150,519 | |||||||||||||||||||||
| Stock-based compensation expense | 429,000 | 429,000 | ||||||||||||||||||||
| Ending Balance at Dec. 31, 2025 | $ 43,000 | $ 537,202,000 | $ (544,177,000) | $ (6,932,000) | ||||||||||||||||||
| Ending Balance (in shares) at Dec. 31, 2025 | 43,480,411 |
| X | ||||||||||
- Definition Reclassification of warrant liability upon exercise. No definition available.
|
| X | ||||||||||
- Definition Stock issued during period shares common stock issued under private placement offering net of issuance costs. No definition available.
|
| X | ||||||||||
- Definition Stock issued during period shares common stock issued under warrant inducement agreement net of issuance costs. No definition available.
|
| X | ||||||||||
- Definition Common stock issued under securities purchase agreements, shares No definition available.
|
| X | ||||||||||
- Definition Stock issued during period value common stock issued under private placement offering net of issuance costs. No definition available.
|
| X | ||||||||||
- Definition Stock issued during period value common stock issued under warrant inducement agreement net of issuance costs. No definition available.
|
| X | ||||||||||
- Definition Common stock issued under securities purchase agreements. No definition available.
|
| X | ||||||||||
- Definition Stock issued during period shares common stock issued under registered direct offering net of issuance costs. No definition available.
|
| X | ||||||||||
- Definition Warrant exercise value. No definition available.
|
| X | ||||||||||
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of shares issued which are neither cancelled nor held in the treasury. No definition available.
|
| X | ||||||||||
- Definition Number of shares issued during the period as a result of the conversion of convertible securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The gross value of stock issued during the period upon the conversion of convertible securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|